Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients
Aim: To evaluate changes in liver histology in patients with human immunodeficiency virus/hepatitis C virus coinfection non-responders to a suboptimal Interferon + Ribavirine regimen. Materials and methods: We investigated 49 patients with two sequential liver biopsies: 18 were non-responders to Int...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-03-01
|
Series: | Brazilian Journal of Infectious Diseases |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1413867013002389 |
id |
doaj-b19861420ba74c959908a6665c891dbb |
---|---|
record_format |
Article |
spelling |
doaj-b19861420ba74c959908a6665c891dbb2020-11-25T03:56:13ZengElsevierBrazilian Journal of Infectious Diseases1413-86702014-03-01182164169S1413-86702014000200164Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patientsCaterina Sagnelli0Caterina Uberti-Foppa1Laura Galli2Giuseppe Pasquale3Nicola Coppola4Luca Albarello5Carlo Doglioni6Adriano Lazzarin7Evangelista Sagnelli8Clinic of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, Naples, ItalyClinic of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, ItalyClinic of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, ItalyDepartment of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, ItalyDepartment of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, ItalyDepartment of Pathology, San Raffaele Scientific Institute, Milan, ItalyDepartment of Pathology, San Raffaele Scientific Institute, Milan, ItalyClinic of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, ItalyDepartment of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy; Corresponding author at: Department of Public Medicine, Section of Infectious Diseases, Second University of Naples, via L. Armanni, N° 3, 80135 Naples, Italy.Aim: To evaluate changes in liver histology in patients with human immunodeficiency virus/hepatitis C virus coinfection non-responders to a suboptimal Interferon + Ribavirine regimen. Materials and methods: We investigated 49 patients with two sequential liver biopsies: 18 were non-responders to Interferon + Ribavirine treatment (Group hepatitis C virus Rx) administered after the 1st liver biopsy who underwent a 2nd liver biopsy after a median period of 3.92 year and 31 were patients who remained untreated for hepatitis C virus disease (Group hepatitis C virus untreated) after the 1st liver biopsy because of refusal and underwent a 2nd liver biopsy after a median period of 5.05-years. Most patients in both groups were under highly active antiretroviral therapy. At the time of 1st liver biopsy similar degrees of necro-inflammation, fibrosis and steatosis were observed in both groups. Changes in liver lesions between 1st and 2nd liver biopsys were adjusted for different intervals between liver biopsys by a mathematic formula. Results: Liver fibrosis did not change in 88.9% of patients in Group hepatitis C virus Rx and in 77.4% in Group hepatitis C virus untreated. A marked deterioration in liver fibrosis was observed in 5 (16%) patients in Group hepatitis C virus untreated and in none in Group hepatitis C virus treated. Necro-inflammation and steatosis remained substantially unchanged in both groups. Conclusion: Liver histology remained substantially unchanged in human immunodeficiency virus/hepatitis C virus patients non-responder to anti-hepatitis C virus therapy over 4 years observation, suggesting an effective anti-hepatitis C virus early treatment for all hepatitis C virus/human immunodeficiency virus coinfected patients who can reasonably tolerate therapy. Keywords: HIV/HCV coinfection, HIV infection, HIV/HCV coinfection liver histology, Liver fibrosishttp://www.sciencedirect.com/science/article/pii/S1413867013002389 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Caterina Sagnelli Caterina Uberti-Foppa Laura Galli Giuseppe Pasquale Nicola Coppola Luca Albarello Carlo Doglioni Adriano Lazzarin Evangelista Sagnelli |
spellingShingle |
Caterina Sagnelli Caterina Uberti-Foppa Laura Galli Giuseppe Pasquale Nicola Coppola Luca Albarello Carlo Doglioni Adriano Lazzarin Evangelista Sagnelli Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients Brazilian Journal of Infectious Diseases |
author_facet |
Caterina Sagnelli Caterina Uberti-Foppa Laura Galli Giuseppe Pasquale Nicola Coppola Luca Albarello Carlo Doglioni Adriano Lazzarin Evangelista Sagnelli |
author_sort |
Caterina Sagnelli |
title |
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients |
title_short |
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients |
title_full |
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients |
title_fullStr |
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients |
title_full_unstemmed |
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients |
title_sort |
anti-hepatitis c virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis c virus coinfected patients |
publisher |
Elsevier |
series |
Brazilian Journal of Infectious Diseases |
issn |
1413-8670 |
publishDate |
2014-03-01 |
description |
Aim: To evaluate changes in liver histology in patients with human immunodeficiency virus/hepatitis C virus coinfection non-responders to a suboptimal Interferon + Ribavirine regimen. Materials and methods: We investigated 49 patients with two sequential liver biopsies: 18 were non-responders to Interferon + Ribavirine treatment (Group hepatitis C virus Rx) administered after the 1st liver biopsy who underwent a 2nd liver biopsy after a median period of 3.92 year and 31 were patients who remained untreated for hepatitis C virus disease (Group hepatitis C virus untreated) after the 1st liver biopsy because of refusal and underwent a 2nd liver biopsy after a median period of 5.05-years. Most patients in both groups were under highly active antiretroviral therapy. At the time of 1st liver biopsy similar degrees of necro-inflammation, fibrosis and steatosis were observed in both groups. Changes in liver lesions between 1st and 2nd liver biopsys were adjusted for different intervals between liver biopsys by a mathematic formula. Results: Liver fibrosis did not change in 88.9% of patients in Group hepatitis C virus Rx and in 77.4% in Group hepatitis C virus untreated. A marked deterioration in liver fibrosis was observed in 5 (16%) patients in Group hepatitis C virus untreated and in none in Group hepatitis C virus treated. Necro-inflammation and steatosis remained substantially unchanged in both groups. Conclusion: Liver histology remained substantially unchanged in human immunodeficiency virus/hepatitis C virus patients non-responder to anti-hepatitis C virus therapy over 4 years observation, suggesting an effective anti-hepatitis C virus early treatment for all hepatitis C virus/human immunodeficiency virus coinfected patients who can reasonably tolerate therapy. Keywords: HIV/HCV coinfection, HIV infection, HIV/HCV coinfection liver histology, Liver fibrosis |
url |
http://www.sciencedirect.com/science/article/pii/S1413867013002389 |
work_keys_str_mv |
AT caterinasagnelli antihepatitiscvirustreatmentmaypreventtheprogressionofliverfibrosisinnonresponderhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients AT caterinaubertifoppa antihepatitiscvirustreatmentmaypreventtheprogressionofliverfibrosisinnonresponderhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients AT lauragalli antihepatitiscvirustreatmentmaypreventtheprogressionofliverfibrosisinnonresponderhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients AT giuseppepasquale antihepatitiscvirustreatmentmaypreventtheprogressionofliverfibrosisinnonresponderhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients AT nicolacoppola antihepatitiscvirustreatmentmaypreventtheprogressionofliverfibrosisinnonresponderhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients AT lucaalbarello antihepatitiscvirustreatmentmaypreventtheprogressionofliverfibrosisinnonresponderhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients AT carlodoglioni antihepatitiscvirustreatmentmaypreventtheprogressionofliverfibrosisinnonresponderhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients AT adrianolazzarin antihepatitiscvirustreatmentmaypreventtheprogressionofliverfibrosisinnonresponderhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients AT evangelistasagnelli antihepatitiscvirustreatmentmaypreventtheprogressionofliverfibrosisinnonresponderhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients |
_version_ |
1724466302052990976 |